There is good news about Covaxin made by Bharat Biotech. US-based pharma company Ocugen is preparing for commercial production of Covaxin. The company has started the process of obtaining approval for emergency use and supply of Covaxin. Once approved, OcuGen wants to make 100 million doses of our vaccine in the first year itself.
This is considered a big diplomatic success for the Indian company, as the US is currently vaccinating its citizens with Pfizer and Moderna. Experts say that Covaxin is very easy to maintain and is quite affordable. In such a situation, the demand for vaccination in America can be met through this, while it will also create jobs in America.
Covaxin is developed by Bharat Biotech of Hyderabad in association with ICMR. It has also been approved for children in India.
India Biotech to Transfer Technology
Dr. Shankar Musunuri, CEO and Co-Founder of OcuGen, said, “There are plans to launch Covaxin in the US market in the coming months. Bharat Biotech has a stellar record since its inception. He has 140 global patents to his name. He makes more than 16 vaccines. Covaxin is registered in 116 countries and has been approved by WHO. Once approved by the FDA, we will transfer the technology to make Covaxin with Bharat Biotech in the US.
Covaxin can be a game changer in
America According to data, America has so far reserved 110 million doses including Pfizer-BioNtech, Moderna and Johnson-Johnson. 90% of these doses are from Pfizer and Moderna. Dr Shankar says that Covaxin will prove to be safe and effective for adults as well as children in America.
In India, Covaxin was initially approved for emergency use along with CoviShield.
Covaccines are inexpensive compared to the rest of the vaccines currently available in the US. It is also easier to maintain and distribute than Pfizer and Moderna. It can be stored at room temperature for up to 3 months.